Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9452W HIGH $9.04
Volume
50.36 K
Value Traded
3.88 M
Short % Float
3.35%
+4.04%Week
+8.83%1 Month
+72.87%3 Month
+56.63%6 Month
-65.8%5 Year
-65.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.02 B
EPS (TTM)
-0.26
P/E Ratio
-
Ent. Value
2.33 B
Total Shares
356.82 M
Float Shares
173.61 M
Insiders
55.53%
Institutions
11.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALVO Catalyst Timeline
Dated clinical, regulatory and corporate events for Alvotech
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alvotech
532Total events
18Upcoming
220Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Alvotech and LOTTE Biologics announce long-term strategic manufacturing partnership for multiple antibody biosimilars
▲Manufacturing MilestoneAVT02/MLApprovedCMC / Inspection
FDA approves BLA supplement enabling AVT02 drug substance manufacture in DSM2 suite
▲FDA Filing AcceptedAVT80FiledRegulatory Filing
FDA accepted for review BLA for AVT80
ulcerative colitis and Crohn's diseasesource ↗
▲Partnership / LicenseAVT34Corporate
Licensing and commercialization agreement with Lotus for AVT34
oncologysource ↗
▲Partnership / LicenseAVT87Corporate
Licensing and commercialization agreement with Lotus for AVT87
hemophilia Asource ↗
▲Pre Approval InspectionCMC / Inspection
FDA closes inspection of Reykjavik manufacturing facility with VAI classification
▲Form 483 IssuedCMC / Inspection
FDA closes inspection of Reykjavik manufacturing facility with VAI classification
●BLA SubmissionAVT05ApprovedRegulatory Filing
Resubmission of BLA for AVT05 (biosimilar to Simponi)
●BLA SubmissionAVT06ApprovedRegulatory Filing
Resubmission of BLA for AVT06 (biosimilar to Eylea)
●BLA SubmissionAVT05ApprovedRegulatory Filing
BLA resubmission for AVT05 (biosimilar to Simponi)
biosimilar to Simponi (golimumab)source ↗
●BLA SubmissionAVT06ApprovedRegulatory Filing
BLA resubmission for AVT06 (biosimilar to Eylea)
biosimilar to Eylea (aflibercept)source ↗
▲Manufacturing MilestoneAVT02/MLApprovedCMC / Inspection
FDA closes most recent inspection of Reykjavik facility with Voluntary Action Indicated classification
▲Manufacturing MilestoneCMC / Inspection
FDA closes most recent inspection of Reykjavik facility with VAI classification
▲Product LaunchAVT05ApprovedPost-Market
Launch of additional biosimilars in Japan in H1 2026
golimumab biosimilarsource ↗
▼Equity OfferingCorporate
Concurrent private placement of 17,826,666 shares at $3.75 to EEA investors, expected to close June 25, 2026
▼Equity OfferingCorporate
Priced and allocated 22,666,667 shares at $3.75 in US public offering, expected to close June 17, 2026
▼Equity OfferingCorporate
Pricing of $152 million public offering and concurrent private placement
▼Equity OfferingCorporate
Alvotech announces $125 million public offering of shares in the US and concurrent private placement to institutional investors in the EEA
▲BLA SubmissionAVT16FiledRegulatory Filing
FDA accepted BLA for AVT16
ulcerative colitis, Crohn's diseasesource ↗
▲EMA ValidationAVT16FiledEx-US Regulatory
EMA validated MAA for AVT16 and AVT80
ulcerative colitis, Crohn's diseasesource ↗
▲FDA Filing AcceptedAVT16FiledRegulatory Filing
FDA accepted BLA filing for AVT16 (biosimilar to Entyvio)
ulcerative colitis, Crohn's diseasesource ↗
▲EU MAA SubmissionAVT16FiledEx-US Regulatory
EMA accepted MAA for AVT16 (biosimilar to Entyvio)
ulcerative colitis, Crohn's diseasesource ↗
●BLA SubmissionAVT05ApprovedRegulatory Filing
Resubmission of BLA for AVT05 (biosimilar to Simponi/Simponi Aria)
chronic inflammatory conditionssource ↗
●BLA SubmissionAVT06ApprovedRegulatory Filing
Resubmission of BLA for AVT06 (biosimilar to Eylea 2 mg)
retinal disorderssource ↗
▲FDA Filing AcceptedAVT16FiledRegulatory Filing
FDA accepts BLA submission for AVT16 (biosimilar to Entyvio)
▼Form 483 IssuedCMC / Inspection
FDA issued Form 483 after cGMP surveillance inspection at Reykjavik facility
▲Manufacturing MilestoneCMC / Inspection
FDA completes inspection of Alvotech's manufacturing facility in Reykjavik
●EU MAA SubmissionAVT16FiledEx-US Regulatory
EMA submission for AVT16 (biosimilar to Entyvio)
●EU MAA SubmissionAVT80FiledEx-US Regulatory
EMA submission for AVT80 (biosimilar to Entyvio)
▲Trial InitiationAVT29Trial
Commenced pivotal efficacy and safety study for AVT29 for Eylea HD
biosimilar to Eylea HD (aflibercept high dose)source ↗
▲Partnership / LicenseCorporate
Entered strategic manufacturing agreement with FUJIFILM Biotechnologies
●Manufacturing MilestoneCMC / Inspection
Routine cGMP surveillance FDA inspection at Reykjavik facility completed
▲Product LaunchAVT06ApprovedPost-Market
AVT06 launch in European Economic Area and other ex-US markets
retinal diseasessource ↗
▲Pre Approval InspectionCMC / Inspection
FDA closed inspection of Reykjavik facility with VAI classification
▲Form 483 IssuedCMC / Inspection
FDA closed inspection of Reykjavik facility with VAI classification
▲FDA Filing AcceptedAVT16FiledRegulatory Filing
FDA accepted for review BLA for AVT16
ulcerative colitis and Crohn's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ALVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-02 | AVT05 (golimumab biosimilar; Simponi reference) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$473M
Pipeline Value
$2.2B
Commercial Value
Fair Value
Valuation Signal
4
Drugs Scored
0.8x
rNPV / MCap
Top 38%
Small Cap(rank 251 of 658)
Percentile Rank
Alvotech carries a moderate pipeline score (40/100), with $781M risk-adjusted pipeline value, led by AVT29 in Diabetic Macular Edema (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026) Revenue $492M x 4.4 = $2.2B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AVT29 Small moleculeNCT07489131 | Diabetic Macular Edema | Phase 3 | RECRUITING | 256 | Jan 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALVO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ALVO for Q2 2026. | ||||
ALVO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALVO ranks across every disease it competes in
Competitive Position is a premium feature
See how ALVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALVO News
ALVO▼ -0.4%today
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Alvotech and LOTTE Biologics have entered a long-term manufacturing partnership to produce multiple biosimilar products at LOTTE's Syracuse facility in New York. This collaboration aims to enhance Alvotech's global manufacturing capacity and meet growing demand for biosimilars. The Syracuse facility boasts significant bioreactor capacity and has recently passed an FDA inspection with no observations, indicating strong quality standards.
Read more →ALVO▲ +12.1%on this newsshared move
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Alvotech received FDA approval for an additional manufacturing suite for its biosimilar AVT02, marketed as SIMLANDI, at its Reykjavik facility. This approval effectively doubles the drug substance manufacturing capacity for U.S. supply and confirms the resolution of prior FDA inspection-related matters. The new suite will enhance operational flexibility and support future applications for other biosimilars.
Read more →ALVOAlvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
Alvotech announced that the FDA has accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This acceptance marks a key milestone in Alvotech's biosimilar program, which also includes AVT16 for intravenous use. The application is backed by comprehensive data demonstrating biosimilarity, and if approved, AVT80 will enhance treatment options for patients.
Read more →ALVOAlvotech to present at upcoming investor conferences in September
Alvotech will present at two major investor conferences in September 2026. Robert Wessman and Dr. Balaji V. Prasad will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference and host investor meetings at Deutsche Bank's Healthcare Summit. A live webcast will be available for public access.
Read more →ALVOAlvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Alvotech has entered a licensing and commercialization agreement with Lotus Pharmaceutical for two biosimilar candidates, AVT34 and AVT87, targeting the U.S. and selected Asian markets. This agreement allows Alvotech to directly commercialize these products in the U.S. while Lotus handles commercialization in eight Asian countries. The deal could yield up to $150 million in payments for Alvotech.
Read more →ALVO▲ +7%on this news· ran to +27% by day 3shared move
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
Alvotech reported its financial results for the first half of 2026, showing a decrease in revenue and adjusted EBITDA compared to the previous year. The company has resubmitted Biologics License Applications for several biosimilars and anticipates FDA decisions in Q4 2026. Despite revenue challenges, Alvotech maintains strong commercial demand and has secured additional funding to support its operations.
Read more →ALVOAlvotech to Report Financial Results for H1 2026
Alvotech will announce its financial results for the first half of 2026 on August 19, 2026, after market close. A live webcast with a Q&A session is scheduled for August 20, 2026. The company continues to focus on developing biosimilar medicines, with five already approved and a robust pipeline targeting various health conditions.
Read more →ALVO▲ +13.9%on this news
Alvotech announces successful closure of FDA inspection of manufacturing facility
Alvotech announced the successful closure of an FDA inspection of its Reykjavik manufacturing facility, which was classified as Voluntary Action Indicated. CEO Lisa Graver highlighted the company's efforts to enhance quality systems. The company is also advancing its biosimilar pipeline, with several Biologics License Applications submitted and accepted by the FDA.
Read more →ALVOTransactions of Managers and Closely Associated Persons
Alvotech has filed two documents with the Luxembourg CSSF, detailing transactions involving managers and closely associated persons. The filings announce the pledging of 88,940,619 shares and 7,007,321 depository receipts on shares by Celtic. This disclosure is part of regulatory compliance regarding share transactions.
Read more →ALVOAlvotech further strengthens liquidity by securing term loan facility of $75 million
Alvotech has secured a $75 million term loan facility led by GoldenTree Asset Management, enhancing its liquidity and financial position. This follows a recent $165 million equity raise, bringing total new capital access to $240 million. The funds will support Alvotech's R&D pipeline and global product launches, reflecting growing confidence in the company's strategy.
Read more →ALVOAlvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Alvotech has successfully closed a public offering, raising approximately $165 million through the sale of ordinary shares. The offering included the full exercise of underwriters' options and a concurrent private placement. The funds will be utilized for the development of biosimilar assets and general corporate purposes. The offering was conducted under a previously filed registration statement with the SEC.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Alvotech has announced the pricing of a public offering of 22,666,667 ordinary shares at $3.75 each, aiming to raise approximately $152 million. The offering is set to close on June 17, 2026, and includes a concurrent private placement of 17,826,666 shares. Proceeds will be used for the development of biosimilar products and general corporate purposes.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Alvotech has announced a proposed public offering of $125 million in ordinary shares, along with a concurrent private placement. The proceeds will be used to support the development of biosimilar assets and general corporate purposes. The offering is subject to market conditions, and the allocation of shares between the public offering and private placement is yet to be determined.
Read more →ALVO▲ +19.8%on this news
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
Alvotech announced the FDA's acceptance of its Biologics License Application for AVT16, an interchangeable biosimilar to Entyvio. This development is part of Alvotech's strategy to enhance access to biosimilar medicines. The application is backed by extensive data demonstrating biosimilarity, and if approved, AVT16 will provide more treatment options for patients.
Read more →ALVO▲ +19.1%on this news· ran to +32% by day 3shared move
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria , and AVT06, a proposed biosimilar to Eylea
Alvotech has announced the resubmission of Biologics License Applications for AVT05, a biosimilar to Simponi, and AVT06, a biosimilar to Eylea, to the FDA. This follows responses to FDA feedback regarding the company’s manufacturing facility in Reykjavik. The resubmissions represent a significant milestone as Alvotech continues to strengthen its quality systems and processes. The FDA is expected to conduct a review within six months, in line with standard regulatory timelines.
Read more →ALVOAlvotech to present at upcoming investor conferences in June 2026
Alvotech has announced that its Founder and Executive Chairman, Robert Wessman, along with Chief Strategy Officer Dr. Balaji V. Prasad, will present at investor conferences in June 2026. The events will be accessible via live audio webcasts, with recordings available for 90 days post-event. Alvotech continues to strengthen its position in the biosimilar market with a diverse pipeline.
Read more →ALVO▼ -6.8%on this newsshared move
Alvotech to present at upcoming investor conferences in June
Alvotech has announced its participation in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Key executives, Robert Wessman and Dr. Balaji V. Prasad, will engage in fireside chats to discuss the company's developments. Live webcasts will be accessible to the public, with recordings available post-event.
Read more →ALVOAlvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
Alvotech has renewed its market-making agreement with Islandsbanki to enhance trading of ALVO shares on Nasdaq Iceland. The agreement stipulates that Islandsbanki will maintain a minimum market value of ISK 8 million in bid and ask quotes. The maximum spread between quotes is set at 2.5%, with a daily trading limit of ISK 16 million. The agreement has no fixed term and can be terminated with a 7-day notice.
Read more →ALVO▲ +10.1%on this news
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
Alvotech has successfully completed a routine FDA cGMP surveillance inspection at its Reykjavik facility, receiving a Form 483 with observations that the company believes can be quickly addressed. This positions Alvotech to resubmit its Biologics License Applications within the quarter. The company remains optimistic about receiving FDA approval for these applications in 2026.
Read more →ALVO▲ +10.1%on this newsshared move
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
Alvotech has successfully completed a routine FDA surveillance inspection at its Reykjavik facility, receiving a Form 483 with no substantial issues noted. The company plans to resubmit its Biologics License Applications in the second quarter of 2026, bolstered by the inspection's positive outcome. Alvotech continues to anticipate FDA approval for its relevant BLAs within the year.
Read more →About Alvotech
HeadquartersLuxembourg
Founded2021
BIOPHARMAWATCH ELITE PLUS
Trade the next ALVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime